Please assess the completion status of the following clinical trial:

Trial Title: Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 50 years of age or older.~* Diagnosis of early Alzheimer's disease (AD) or mild cognitive impairment (MCI) at minimum. All following criteria must be met:~  * Probable MCI or AD consistent with criteria outlined in (McKhann et al 2011, Petersen et al 2018).~ * Mini Mental State Examination (MMSE) score between 12 and 26.~ * Modified Hachinski Ischemia Scale (MHIS) score of \<= 4~ * Short form Geriatric Depression Scale (GDS) score of \<= 6.~ * PET scan confirming amyloid plaque load using Amyvid (18F-Florbetapir).~* Ability to provide informed consent.~Exclusion Criteria:~* Contraindication for Magnetic Resonance Imaging (MRI).~* Contra-indication history or hypersensitivity to MRI contrast agents (e.g., Dotarem) or microbubbles (e.g., Definity).~* Prior brain surgery, including deep brain stimulation.~* Metallic implants.~* Moderate or severe uncontrolled hypertension (systolic blood pressure \> 140 mmHg).~* Abnormal coagulation profile, e.g. hemophilia A or B.~* Coagulopathy or under anticoagulant therapy.~* History of stroke or cardiovascular disease.~* Active/detectable gingivitis, herpes simplex, hepatitis, tuberculosis, and minor skin or respiratory infections.~* History of seizure disorder.~* History of asthma or allergies to food or medication with significant symptoms in past 3 years.~* Severe brain atrophy.~* Inability to comply with the procedures of the protocol, including follow-up MRI scans.~* Pregnancy or lactation.~* Impaired renal function with estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m2 provided by a standard blood test at maximum 2 weeks prior to the ultrasound treatment.~* Active infection/inflammation.~* Acute or chronic hemorrhages, i.e. \> 4 lobar microbleeds, and no siderosis or macrohemorrhages.~* Tumors or space occupying lesions.~* Meningeal enhancements.~* Intracranial hypotension.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Focused ultrasound treatment (Type: EXPERIMENTAL): Neuronavigation-guided focused ultrasound treatment in Alzheimer's disease patients using a single-element transducer in conjunction with Definity Microbubbles (10 μl/kg).

Based on this trial design, predict the completion outcome and termination type (if applicable).